Special Focus Commentary
Volume 8, Issue 8
Purchase or Subscribe
Pages 1143 - 1145http://dx.doi.org/10.4161/hv.21203
: cancer biomarkers, colon cancer, kras, tumor heterogeneity
Authors: Mike Cusnir and Ludmila Cavalcante View affiliations
Advances in the molecular study of cancer have focused on biomarkers in the setting of tumor-driving mutations within the great heterogeneity of the tumor genomic landscape. It is clearly recognized now that even two tumors originating from the same organ even if histological they appear similar their behavior and response to therapy can be different. These findings have increased interest and research to find truly prognostic and predictive biomarkers to serve as tools in better assessing the natural course of disease and response to treatments in the hope of truly individualizing cancer therapy in the future.
Received: June 18, 2012; Accepted: June 21, 2012; Published Online: August 1, 2012
Full Text - Ahead of Print Available - Log in!